Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AMIT R PALIWAL

Allopathic & Osteopathic Physicians Family Medicine

NPI
1790881159
CMS profile
81770
Location
POMONA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$428.97

25 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $428.97 25

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AMIT R PALIWAL

NPI 1790881159 · CMS profile ID 81770

Allopathic & Osteopathic Physicians / Family Medicine

POMONA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790881159?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AMIT R PALIWAL, NPI 1790881159, CMS profile ID 81770. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790881159?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). AMIT R PALIWAL, NPI 1790881159, CMS profile ID 81770. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790881159?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
AMIT R PALIWAL, NPI 1790881159, CMS profile ID 81770, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1790881159?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

25 matching records · $428.97 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 25 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–25 of 25.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amarin Pharma Inc. $11.0412/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815333139 CMS
Amarin Pharma Inc. $19.2508/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815333141 CMS
Novartis Pharmaceuticals Corporation $18.4908/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813138015 CMS
Amgen Inc. $20.9308/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825133229 CMS
PFIZER INC. $21.6407/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833560053 CMS
Biohaven Pharmaceuticals, Inc. $23.2707/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852584779 CMS
Janssen Pharmaceuticals, Inc $16.0107/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788690175 CMS
Amgen Inc. $24.5306/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825133225 CMS
PFIZER INC. $20.5306/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833542171 CMS
PFIZER INC. $6.8306/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833563889 CMS
Xeris Pharmaceuticals, Inc. $16.4205/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837438833 CMS
Amgen Inc. $13.3305/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825133233 CMS
United Therapeutics Corporation $14.5805/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839129439 CMS
PFIZER INC. $18.5505/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833407475 CMS
Novartis Pharmaceuticals Corporation $19.7505/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813138011 CMS
SK Life Science, Inc. $19.1704/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826853931 CMS
PFIZER INC. $13.6704/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833569763 CMS
Biohaven Pharmaceuticals, Inc. $24.0704/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852584777 CMS
Janssen Pharmaceuticals, Inc $15.1504/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788690177 CMS
PFIZER INC. $15.3003/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833466321 CMS
E.R. Squibb & Sons, L.L.C. $21.2203/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783410693 CMS
PFIZER INC. $15.2402/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833570949 CMS
Merck Sharp & Dohme Corporation $14.0702/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848538443 CMS
Teva Pharmaceuticals USA, Inc. $12.9202/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839510477 CMS
PFIZER INC. $13.0101/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833442073 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,553.93 9
PY2020 $223.29 13
PY2021 $428.97 25
PY2022 $224.04 9
PY2023 $595.36 30
PY2024 $2,420.66 49
PY2025 $474.30 17

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $336,771.75 76
PY2024 Principal investigator $1,437,539.26 120
PY2023 Principal investigator $2,154,474.59 360
PY2022 Principal investigator $1,373,629.94 603
PY2021 Principal investigator $148,509.98 11
PY2020 Principal investigator $14,597.00 9
PY2019 Principal investigator $78,504.30 23

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

360 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $1,606.64 12/27/2023 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045878054
Principal investigator 1 ModernaTX, Inc. $36,064.49 12/26/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1042137311
Principal investigator 1 Janssen Research & Development, LLC $14,303.00 12/22/2023 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986103745
Principal investigator 1 ModernaTX, Inc. $7,500.00 12/22/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1042137317
Principal investigator 1 PFIZER INC. $1,037.76 12/21/2023 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046111259
Principal investigator 1 ModernaTX, Inc. $25,507.71 12/20/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042137353
Principal investigator 1 ModernaTX, Inc. $25,262.92 12/15/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1042137329
Principal investigator 1 ModernaTX, Inc. $821.34 12/14/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136817
Principal investigator 1 ModernaTX, Inc. $821.34 12/14/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136823
Principal investigator 1 ModernaTX, Inc. $821.34 12/14/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136829
Principal investigator 1 ModernaTX, Inc. $821.34 12/14/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136835
Principal investigator 1 ModernaTX, Inc. $821.34 12/14/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042137365
Principal investigator 1 ModernaTX, Inc. $821.34 12/14/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042137371
Principal investigator 1 ModernaTX, Inc. $821.34 12/14/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042137377
Principal investigator 1 ModernaTX, Inc. $821.34 12/14/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042137383
Principal investigator 1 ModernaTX, Inc. $821.34 12/14/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042137389
Principal investigator 1 ModernaTX, Inc. $821.34 12/14/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042137395
Principal investigator 1 ModernaTX, Inc. $821.34 12/14/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042137401
Principal investigator 1 ModernaTX, Inc. $821.34 12/14/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042137407
Principal investigator 1 ModernaTX, Inc. $821.34 12/14/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042137413
Principal investigator 1 ModernaTX, Inc. $821.34 12/14/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042137419
Principal investigator 1 ModernaTX, Inc. $821.34 12/14/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042137425
Principal investigator 1 ModernaTX, Inc. $821.34 12/14/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042137431
Principal investigator 1 ModernaTX, Inc. $821.34 12/14/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042137437
Principal investigator 1 ModernaTX, Inc. $821.34 12/14/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042137443
Principal investigator 1 ModernaTX, Inc. $821.34 12/14/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042137449
Principal investigator 1 ModernaTX, Inc. $821.34 12/14/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042137455
Principal investigator 1 ModernaTX, Inc. $821.34 12/14/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042137461
Principal investigator 1 ModernaTX, Inc. $821.34 12/14/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042137467
Principal investigator 1 ModernaTX, Inc. $821.34 12/14/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042137473
Principal investigator 1 ModernaTX, Inc. $821.34 12/14/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042137479
Principal investigator 1 PFIZER INC. $4,175.00 12/14/2023 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046250943
Principal investigator 1 ModernaTX, Inc. $4,150.00 12/13/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042137347
Principal investigator 1 ModernaTX, Inc. $158,215.10 12/06/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1042137323
Principal investigator 1 ModernaTX, Inc. $49,801.85 12/06/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1042137335
Principal investigator 1 ModernaTX, Inc. $80,169.94 12/06/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1042137341
Principal investigator 1 ModernaTX, Inc. $58,230.69 12/06/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042137359
Principal investigator 1 Janssen Research & Development, LLC $10,820.00 11/28/2023 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986103749
Principal investigator 1 Janssen Research & Development, LLC $5,758.00 11/28/2023 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986103753
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136621
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136627
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136633
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136639
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136645
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136651
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136657
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136663
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136669
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136675
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136681
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136687
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136693
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136699
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136705
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136713
Principal investigator 1 ModernaTX, Inc. $1,346.40 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136719
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136725
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136731
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136737
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136743
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136749
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136755
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136761
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136767
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136773
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136779
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136783
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136791
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136797
Principal investigator 1 ModernaTX, Inc. $821.34 11/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136803
Principal investigator 1 ModernaTX, Inc. $10,000.00 11/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1042137287
Principal investigator 1 ModernaTX, Inc. $2,000.00 11/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1042137293
Principal investigator 1 PFIZER INC. $43,371.48 11/15/2023 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045868817
Principal investigator 1 ModernaTX, Inc. $82,101.60 11/10/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042137299
Principal investigator 1 ModernaTX, Inc. $59,865.75 11/10/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042137305
Principal investigator 1 ModernaTX, Inc. $1,346.40 10/30/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136597
Principal investigator 1 ModernaTX, Inc. $23,814.00 10/20/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042316557
Principal investigator 1 ModernaTX, Inc. $296.28 10/06/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136591
Principal investigator 1 ModernaTX, Inc. $135.00 10/06/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136603
Principal investigator 1 ModernaTX, Inc. $296.28 10/06/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136615
Principal investigator 1 ModernaTX, Inc. $3,770.00 10/02/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136609
Principal investigator 1 ModernaTX, Inc. $77,701.66 09/27/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042137269
Principal investigator 1 ModernaTX, Inc. $70,128.45 09/20/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042137275
Principal investigator 1 ModernaTX, Inc. $29,077.65 09/20/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042137281
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136363
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136369
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136375
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136381
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136387
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136393
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136399
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136405
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136411
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136417
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136423
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136429
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136435
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136441
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136449
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136455
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136461
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136467
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136473
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136479
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136485
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136491
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136497
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136503
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136509
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136517
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136523
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136529
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136537
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136543
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136549
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136555
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136561
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136567
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136573
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136579
Principal investigator 1 ModernaTX, Inc. $821.34 09/07/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042136585
Principal investigator 1 ModernaTX, Inc. $103,361.84 08/25/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042137263
Principal investigator 1 PFIZER INC. $592.02 08/17/2023 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046045813
Principal investigator 1 ModernaTX, Inc. $22,850.22 08/11/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1042137227
Principal investigator 1 PFIZER INC. $348.46 07/06/2023 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045883055
Principal investigator 1 PFIZER INC. $1,776.06 07/06/2023 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046344499
Principal investigator 1 PFIZER INC. $11,840.40 06/29/2023 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045941677
Principal investigator 1 ModernaTX, Inc. $24,708.23 06/28/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042137233
Principal investigator 1 PFIZER INC. $3,484.60 06/27/2023 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045882297
Principal investigator 1 PFIZER INC. $11,248.38 06/22/2023 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046155241
Principal investigator 1 PFIZER INC. $3,552.12 06/16/2023 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045920081
Principal investigator 1 ModernaTX, Inc. $1,850.00 06/14/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042137239
Principal investigator 1 ModernaTX, Inc. $2,000.00 06/14/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042137245
Principal investigator 1 ModernaTX, Inc. $7,500.00 06/14/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042137251
Principal investigator 1 ModernaTX, Inc. $59,865.75 06/14/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042137257
Principal investigator 1 PFIZER INC. $27,824.94 06/14/2023 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045995615
Principal investigator 1 ModernaTX, Inc. $821.34 06/09/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316533
Principal investigator 1 ModernaTX, Inc. $821.34 06/09/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316535
Principal investigator 1 ModernaTX, Inc. $821.34 06/09/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316537
Principal investigator 1 ModernaTX, Inc. $1,346.40 06/09/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316539
Principal investigator 1 ModernaTX, Inc. $821.34 06/09/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316541
Principal investigator 1 ModernaTX, Inc. $821.34 06/09/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316543
Principal investigator 1 ModernaTX, Inc. $821.34 06/09/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316545
Principal investigator 1 ModernaTX, Inc. $1,346.40 06/09/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316547
Principal investigator 1 ModernaTX, Inc. $821.34 06/09/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316549
Principal investigator 1 ModernaTX, Inc. $821.34 06/09/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316551
Principal investigator 1 ModernaTX, Inc. $821.34 06/09/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316553
Principal investigator 1 ModernaTX, Inc. $821.34 06/09/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316555
Principal investigator 1 PFIZER INC. $41,441.40 06/03/2023 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046018211
Principal investigator 1 ModernaTX, Inc. $47,151.20 05/26/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1042137201
Principal investigator 1 PFIZER INC. $10,929.93 05/26/2023 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045882311
Principal investigator 1 PFIZER INC. $1,776.06 05/25/2023 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046061545
Principal investigator 1 ModernaTX, Inc. $20,217.59 05/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042137221
Principal investigator 1 ModernaTX, Inc. $1,346.40 05/22/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316479
Principal investigator 1 ModernaTX, Inc. $1,346.40 05/22/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316481
Principal investigator 1 ModernaTX, Inc. $1,346.40 05/22/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316483
Principal investigator 1 ModernaTX, Inc. $1,346.40 05/22/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316485
Principal investigator 1 ModernaTX, Inc. $1,346.40 05/22/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316487
Principal investigator 1 ModernaTX, Inc. $1,346.40 05/22/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316489
Principal investigator 1 ModernaTX, Inc. $1,346.40 05/22/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316493
Principal investigator 1 ModernaTX, Inc. $1,346.40 05/22/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316495
Principal investigator 1 ModernaTX, Inc. $1,346.40 05/22/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316499
Principal investigator 1 ModernaTX, Inc. $1,346.40 05/22/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316501
Principal investigator 1 ModernaTX, Inc. $1,346.40 05/22/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316503
Principal investigator 1 ModernaTX, Inc. $1,346.40 05/22/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316505
Principal investigator 1 ModernaTX, Inc. $1,346.40 05/22/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316507
Principal investigator 1 ModernaTX, Inc. $1,346.40 05/22/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316511
Principal investigator 1 ModernaTX, Inc. $1,346.40 05/22/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316513
Principal investigator 1 ModernaTX, Inc. $1,346.40 05/22/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316517
Principal investigator 1 ModernaTX, Inc. $1,346.40 05/22/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316519
Principal investigator 1 ModernaTX, Inc. $1,346.40 05/22/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316521
Principal investigator 1 ModernaTX, Inc. $1,346.40 05/22/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316523
Principal investigator 1 ModernaTX, Inc. $1,346.40 05/22/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316525
Principal investigator 1 ModernaTX, Inc. $1,346.40 05/22/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316527
Principal investigator 1 ModernaTX, Inc. $1,346.40 05/22/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316529
Principal investigator 1 ModernaTX, Inc. $1,346.40 05/22/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316531
Principal investigator 1 ModernaTX, Inc. $1,500.00 05/19/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042137215
Principal investigator 1 PFIZER INC. $641.70 05/16/2023 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046298379
Principal investigator 1 ModernaTX, Inc. $821.34 05/08/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316271
Principal investigator 1 ModernaTX, Inc. $821.34 05/08/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316279
Principal investigator 1 ModernaTX, Inc. $821.34 05/08/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316491
Principal investigator 1 ModernaTX, Inc. $821.34 05/08/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316497
Principal investigator 1 ModernaTX, Inc. $821.34 05/08/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316509
Principal investigator 1 ModernaTX, Inc. $821.34 05/08/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316515
Principal investigator 1 Mylan Inc. $400.33 05/03/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1038725275
Principal investigator 1 ModernaTX, Inc. $79,919.90 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1042137195
Principal investigator 1 ModernaTX, Inc. $23,579.70 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042137207
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316261
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316263
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316265
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316267
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316269
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316273
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316275
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316277
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316281
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316283
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316285
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316287
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316289
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316291
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316293
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316295
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316297
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316299
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316301
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316303
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316305
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316307
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316309
Principal investigator 1 ModernaTX, Inc. $1,346.40 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316311
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316313
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316315
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316317
Principal investigator 1 ModernaTX, Inc. $1,346.40 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316319
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316321
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316323
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316325
Principal investigator 1 ModernaTX, Inc. $1,346.40 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316327
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316329
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316331
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316333
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316335
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316337
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316339
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316341
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316343
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316345
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316347
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316349
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316351
Principal investigator 1 ModernaTX, Inc. $302.16 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316353
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316355
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316357
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316359
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316361
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316363
Principal investigator 1 ModernaTX, Inc. $821.34 05/01/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316365
Principal investigator 1 ModernaTX, Inc. $1,900.00 04/27/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316259
Principal investigator 1 PFIZER INC. $641.70 04/21/2023 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046278987
Principal investigator 1 ModernaTX, Inc. $150.00 04/14/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042316131
Principal investigator 1 PFIZER INC. $80,994.96 04/13/2023 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046308881
Principal investigator 1 PFIZER INC. $82,935.24 04/12/2023 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046216911
Principal investigator 1 PFIZER INC. $641.70 04/05/2023 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046184847
Principal investigator 1 Mylan Inc. $2,233.74 03/30/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1038725263
Principal investigator 1 ModernaTX, Inc. $41,586.57 03/29/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1042137189
Principal investigator 1 Mylan Inc. $2,407.30 03/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1038725269
Principal investigator 1 ModernaTX, Inc. $821.34 03/13/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316225
Principal investigator 1 ModernaTX, Inc. $1,346.40 03/13/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316227
Principal investigator 1 ModernaTX, Inc. $821.34 03/13/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316229
Principal investigator 1 ModernaTX, Inc. $821.34 03/13/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316231
Principal investigator 1 ModernaTX, Inc. $821.34 03/13/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316233
Principal investigator 1 ModernaTX, Inc. $669.27 03/13/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316235
Principal investigator 1 ModernaTX, Inc. $821.34 03/13/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316237
Principal investigator 1 ModernaTX, Inc. $821.34 03/13/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316239
Principal investigator 1 ModernaTX, Inc. $669.27 03/13/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316241
Principal investigator 1 ModernaTX, Inc. $1,346.40 03/13/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316243
Principal investigator 1 ModernaTX, Inc. $821.34 03/13/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316245
Principal investigator 1 ModernaTX, Inc. $821.34 03/13/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316247
Principal investigator 1 ModernaTX, Inc. $909.18 03/13/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316249
Principal investigator 1 ModernaTX, Inc. $821.34 03/13/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316251
Principal investigator 1 ModernaTX, Inc. $1,346.40 03/13/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316253
Principal investigator 1 ModernaTX, Inc. $821.34 03/13/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316255
Principal investigator 1 ModernaTX, Inc. $821.34 03/13/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316257
Principal investigator 1 PFIZER INC. $6,417.00 03/09/2023 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046186791
Principal investigator 1 ModernaTX, Inc. $67,522.88 03/03/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1042137177
Principal investigator 1 ModernaTX, Inc. $55,841.82 03/03/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1042137183
Principal investigator 1 PFIZER INC. $96,452.34 02/28/2023 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046042701
Principal investigator 1 PFIZER INC. $4,700.00 02/25/2023 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045882639
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316051
Principal investigator 1 ModernaTX, Inc. $669.27 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316053
Principal investigator 1 ModernaTX, Inc. $669.27 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316055
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316057
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316059
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316061
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316063
Principal investigator 1 ModernaTX, Inc. $669.27 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316065
Principal investigator 1 ModernaTX, Inc. $669.27 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316067
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316069
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316071
Principal investigator 1 ModernaTX, Inc. $909.18 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316073
Principal investigator 1 ModernaTX, Inc. $669.27 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316075
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316077
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316079
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316081
Principal investigator 1 ModernaTX, Inc. $669.27 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316083
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316085
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316087
Principal investigator 1 ModernaTX, Inc. $909.18 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316089
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316091
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316093
Principal investigator 1 ModernaTX, Inc. $909.18 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316095
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316097
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316099
Principal investigator 1 ModernaTX, Inc. $669.27 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316101
Principal investigator 1 ModernaTX, Inc. $909.18 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316103
Principal investigator 1 ModernaTX, Inc. $669.27 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316105
Principal investigator 1 ModernaTX, Inc. $669.27 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316107
Principal investigator 1 ModernaTX, Inc. $669.27 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316109
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316111
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316113
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316115
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316117
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316119
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316121
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316123
Principal investigator 1 ModernaTX, Inc. $669.27 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316125
Principal investigator 1 ModernaTX, Inc. $669.27 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316127
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316129
Principal investigator 1 ModernaTX, Inc. $909.18 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316167
Principal investigator 1 ModernaTX, Inc. $669.27 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316169
Principal investigator 1 ModernaTX, Inc. $669.27 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316171
Principal investigator 1 ModernaTX, Inc. $669.27 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316173
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316175
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316177
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316179
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316181
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316183
Principal investigator 1 ModernaTX, Inc. $669.27 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316185
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316187
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316189
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316191
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316193
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316195
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316197
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316199
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316201
Principal investigator 1 ModernaTX, Inc. $669.27 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316203
Principal investigator 1 ModernaTX, Inc. $669.27 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316205
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316207
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316209
Principal investigator 1 ModernaTX, Inc. $669.27 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316211
Principal investigator 1 ModernaTX, Inc. $669.27 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316213
Principal investigator 1 ModernaTX, Inc. $669.27 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316215
Principal investigator 1 ModernaTX, Inc. $669.27 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316217
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316219
Principal investigator 1 ModernaTX, Inc. $821.34 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316221
Principal investigator 1 ModernaTX, Inc. $909.18 02/24/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316223
Principal investigator 1 PFIZER INC. $7,158.06 02/18/2023 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046291843
Principal investigator 1 ModernaTX, Inc. $8,880.00 02/10/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1042137163
Principal investigator 1 ModernaTX, Inc. $200.00 02/10/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1042137171
Principal investigator 1 PFIZER INC. $26,911.22 02/08/2023 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045882343
Principal investigator 1 PFIZER INC. $6,022.32 02/07/2023 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046058861
Principal investigator 1 ModernaTX, Inc. $10,620.44 01/25/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1042137157
Principal investigator 1 ModernaTX, Inc. $909.18 01/12/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316021
Principal investigator 1 ModernaTX, Inc. $669.27 01/12/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316023
Principal investigator 1 ModernaTX, Inc. $909.18 01/12/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316025
Principal investigator 1 ModernaTX, Inc. $909.18 01/12/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316027
Principal investigator 1 ModernaTX, Inc. $669.27 01/12/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316029
Principal investigator 1 ModernaTX, Inc. $669.27 01/12/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316031
Principal investigator 1 ModernaTX, Inc. $669.27 01/12/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316033
Principal investigator 1 ModernaTX, Inc. $669.27 01/12/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316035
Principal investigator 1 ModernaTX, Inc. $909.18 01/12/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316037
Principal investigator 1 ModernaTX, Inc. $909.18 01/12/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316039
Principal investigator 1 ModernaTX, Inc. $669.27 01/12/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316041
Principal investigator 1 ModernaTX, Inc. $909.18 01/12/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316043
Principal investigator 1 ModernaTX, Inc. $1,346.40 01/12/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316045
Principal investigator 1 ModernaTX, Inc. $3,982.82 01/12/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316047
Principal investigator 1 ModernaTX, Inc. $909.18 01/12/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042316049
Principal investigator 1 Mylan Inc. $2,669.98 01/12/2023 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1038725257